Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 15, 2019
Pharmacy Choice - Pharmaceutical News - FDA Approves Phase 3 Trial to Evaluate Oral Carbapenem for Treatment of cUTI [Sudan Tribune] - February 15, 2019

Pharmacy News Article

 2/7/19 - FDA Approves Phase 3 Trial to Evaluate Oral Carbapenem for Treatment of cUTI [Sudan Tribune]

The US Food and Drug Administration (FDA) has accepted Spero Therapeutics Investigational New Drug application for SPR994, a candidate being developed as an oral carbapenem antibiotic for the treatment of complicated urinary tract infections (cUTI).

With the acceptance of the application, the company will initiate enrollment of a phase 3 clinical trial in the United States.

The candidate, SPR994, has an oral formulation of tebipenem, which is a carbapenem-class antibiotic that has been marketed in Japan since 2009 for pediatric infections of pneumonia, otitis media, and sinusitis.

Spero Therapeutics conducted a phase 1, double-blind, placebo-controlled, dosing study in Australia, which enabled dose selection for the phase 3 trial. The company also reports that the candidate has shown potent antibiotic activity against gram-negative bacteria, including E coli-producing extended-spectrum beta-lactamases (ESBLs) and ESBL-producing Klebsiella pneumoniae, similar to IV-administered ertapenem in preclinical studies.

The phase 3 clinical trial, ADAPT-PO, is designed as a double-blind trial that will evaluate the investigational candidate with the current intravenous standard of care, ertapenem. The trial will enroll approximately 2400 patients with either cUTI or acute pyelonephritis in 1 of 2 treatment arms, with participants randomized 1:1 at the point of enrollment.

With the FDAs acceptance of our IND application for SPR994, we are excited to continue our Phase 3 initiation efforts, including opening clinical trial sites for enrollment in the US," Ankit Mahadevia, MD, chief executive officer of Spero Therapeutics, said in a statement. "We look forward to enrolling patients in our single pivotal Phase 3 clinical trial with the hope, following approval, of providing patients with the option for an oral carbapenem to address the serious unmet need of multi-drug resistant infections.

According to the company, the primary endpoint of the trial is combined clinical and microbiological response at the test of cure with a 10% non-inferiority margin versus IV ertapenem.

The trial will feature a lead-in cohort of 70 patients with intensive pharmacokinetics to assess the dose and exposure in cUTI patients. Additionally, the company will conduct parallel ancillary pharmacology studies including a renal insufficiency study.

The interim pharmacokinetic data from the lead-in cohort is expected in the second half of 2019.

Spero Therapeutics also reports that the project has received funding from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority.



(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Feb 18: Management of Schizophrenia & Acute Agitation
Feb 19: Treatment of Atopic Dermatitis (Eczema) & Xerosis (Dry Skin)
Feb 20: Know Your Value, Know Your Worth: Provider Status in Pharmacy
Feb 21: Type II Diabetes: Case Studies and Management Options
Feb 22: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415